KR20240155872A - 헤테로사이클릭 화합물 및 사용 방법 - Google Patents
헤테로사이클릭 화합물 및 사용 방법 Download PDFInfo
- Publication number
- KR20240155872A KR20240155872A KR1020247028976A KR20247028976A KR20240155872A KR 20240155872 A KR20240155872 A KR 20240155872A KR 1020247028976 A KR1020247028976 A KR 1020247028976A KR 20247028976 A KR20247028976 A KR 20247028976A KR 20240155872 A KR20240155872 A KR 20240155872A
- Authority
- KR
- South Korea
- Prior art keywords
- ethyl
- oxo
- dihydropyridine
- carboxamide
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306784P | 2022-02-04 | 2022-02-04 | |
| US63/306,784 | 2022-02-04 | ||
| US202263376595P | 2022-09-21 | 2022-09-21 | |
| US63/376,595 | 2022-09-21 | ||
| PCT/US2023/012307 WO2023150291A2 (en) | 2022-02-04 | 2023-02-03 | Heterocyclic compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240155872A true KR20240155872A (ko) | 2024-10-29 |
Family
ID=87552839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247028976A Pending KR20240155872A (ko) | 2022-02-04 | 2023-02-03 | 헤테로사이클릭 화합물 및 사용 방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230348424A1 (https=) |
| EP (1) | EP4472974A4 (https=) |
| JP (1) | JP2025505609A (https=) |
| KR (1) | KR20240155872A (https=) |
| AU (1) | AU2023215383A1 (https=) |
| CA (1) | CA3243353A1 (https=) |
| CL (1) | CL2024002328A1 (https=) |
| CO (1) | CO2024010726A2 (https=) |
| CR (1) | CR20240362A (https=) |
| IL (1) | IL314594A (https=) |
| MX (1) | MX2024009608A (https=) |
| PE (1) | PE20250681A1 (https=) |
| TW (1) | TW202342461A (https=) |
| WO (1) | WO2023150291A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3229566A1 (en) * | 2021-08-17 | 2023-02-23 | Kanaph Therapeutics Inc. | Sos1 inhibitor and use thereof |
| WO2025163050A1 (en) * | 2024-01-31 | 2025-08-07 | Les Laboratoires Servier | New amide derivatives, pharmaceutical compositions containing them and their uses as sos1 inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201143768A (en) * | 2009-12-15 | 2011-12-16 | Lundbeck & Co As H | Pyridone derivatives as NK3 antagonists |
| WO2016077793A1 (en) * | 2014-11-14 | 2016-05-19 | Children's Hospital Medical Center | Sos1 inhibitors for cancer treatment |
| RS64167B1 (sr) * | 2017-12-21 | 2023-05-31 | Boehringer Ingelheim Int | Benzilamino supstituisani piridopirimidinoni i derivati kao sos1 inhibitori |
| KR20240013792A (ko) * | 2021-05-27 | 2024-01-30 | 슈뢰딩거, 인크. | 헤테로시클릭 화합물 및 사용 방법 |
-
2023
- 2023-02-03 CR CR20240362A patent/CR20240362A/es unknown
- 2023-02-03 TW TW112103933A patent/TW202342461A/zh unknown
- 2023-02-03 CA CA3243353A patent/CA3243353A1/en active Pending
- 2023-02-03 MX MX2024009608A patent/MX2024009608A/es unknown
- 2023-02-03 AU AU2023215383A patent/AU2023215383A1/en active Pending
- 2023-02-03 PE PE2024001747A patent/PE20250681A1/es unknown
- 2023-02-03 KR KR1020247028976A patent/KR20240155872A/ko active Pending
- 2023-02-03 US US18/164,346 patent/US20230348424A1/en active Pending
- 2023-02-03 WO PCT/US2023/012307 patent/WO2023150291A2/en not_active Ceased
- 2023-02-03 IL IL314594A patent/IL314594A/en unknown
- 2023-02-03 EP EP23750219.0A patent/EP4472974A4/en active Pending
- 2023-02-03 JP JP2024546123A patent/JP2025505609A/ja active Pending
-
2024
- 2024-08-02 CL CL2024002328A patent/CL2024002328A1/es unknown
- 2024-08-05 CO CONC2024/0010726A patent/CO2024010726A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL314594A (en) | 2024-09-01 |
| US20230348424A1 (en) | 2023-11-02 |
| JP2025505609A (ja) | 2025-02-28 |
| WO2023150291A2 (en) | 2023-08-10 |
| CA3243353A1 (en) | 2023-08-10 |
| CL2024002328A1 (es) | 2024-12-06 |
| PE20250681A1 (es) | 2025-03-04 |
| EP4472974A2 (en) | 2024-12-11 |
| MX2024009608A (es) | 2024-08-15 |
| CO2024010726A2 (es) | 2024-08-08 |
| EP4472974A4 (en) | 2026-03-25 |
| CR20240362A (es) | 2024-10-03 |
| WO2023150291A3 (en) | 2023-08-31 |
| TW202342461A (zh) | 2023-11-01 |
| AU2023215383A1 (en) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7728367B2 (ja) | がんを処置するために使用され得る尿素誘導体 | |
| US12351571B2 (en) | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | |
| CN113490666A (zh) | 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物 | |
| JP2024521818A (ja) | ヘテロ環式化合物およびその使用方法 | |
| JP2024533975A (ja) | Pi3kアイソフォームアルファを阻害する化合物及びがんを処置するための方法 | |
| KR20240155872A (ko) | 헤테로사이클릭 화합물 및 사용 방법 | |
| WO2022072645A2 (en) | Methods for treating cancer | |
| JP2025535066A (ja) | がんを治療するための方法 | |
| WO2023173083A1 (en) | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer | |
| US20250368634A1 (en) | Phenyl amide compounds and methods of use | |
| EA050352B1 (ru) | Гетероциклические соединения и способы использования | |
| CN118974038A (zh) | 杂环化合物和使用方法 | |
| CN117715642A (zh) | 杂环化合物和使用方法 | |
| EA053149B1 (ru) | Производные мочевины, полезные для лечения онкологического заболевания | |
| HK40128998A (zh) | 治疗癌症的方法 | |
| HK40060213A (en) | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer | |
| HK40060210A (en) | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |